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because they are under pressure from patients, physicians, and
manufacturers to increase access to novel therapies. The success of
pharmaceutical innovation over the last few decades has led to the
availability of many off-patent drugs to treat disease areas with the
greatest public health need. Therefore, the success of public health
programs in improving the health status of the total population is
highly dependent on the efﬁciency of generic drug policies. The
objective of this article was to explore factors inﬂuencing the true
efﬁciency of generic prescription drug policies in supporting public
health initiatives in the developed world. Health care decision makers
often assess the efﬁciency of generic drug policies by the level of price
erosion and market share of generics. Drug quality, bioequivalence, inee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2014.12.012
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est, Pázmány P. 1a. – 1117, Hungary.some cases drug formulations, supply reliability, medical adherence
and persistence, health outcomes, and nondrug costs, however, are
also attributes of success for generic drug policies. Further methodo-
logical research is needed to measure and improve the efﬁciency of
generic drug policies. This also requires extension of the evidence
base of the impact of generic drugs, partly based on real-world
evidence. Multicriteria decision analysis may assist policymakers
and researchers to evaluate the true value of generic drugs.
Keywords: adherence, drug policies, generic drug, multicriteria
decision analysis, price erosion, real-world evidence.
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In December 2011, an international group of health outcomes and
policy researchers from 21 countries have participated in a series
of workshops concerning the current practice around generic
drug policies. The objective of these meetings was to understand
how the success of generic drug policies is measured and
interpreted, to expand the evidence base around generic drug
policies, and to explore the health care and methodological
challenges related to different drug policy initiatives.
The steering committee formed as a consequence of the work-
shops has met several times over the last 2 years. Research teams
of the international expert group conducted several literature
reviews in related areas, for example, on deﬁnition and classiﬁca-
tion of off-patent drugs in emerging markets [1], on physicians’ and
pharmacists’ perspectives on generic drugs and generic substitution
[2], and on the impact of generic substitution on health and
economic outcomes [3]. Several health policy workshops have been
conducted at different scientiﬁc events, including the HTAiconference in Seoul, the Latin American ISPOR meeting in Buenos
Aires, the European ISPOR meeting in Dublin, the European Health
Policy Forum in Gastein, and the Asian ISPOR meeting in Beijing as
well as dedicated roundtable discussions of the subject in Latin
America and Asia with a broad range of health care decision
makers and payer representatives throughout 2012 to 2014.
The objective of this article was to introduce the topic of
variance in generic drug purchasing policies, and their potential
impact on the efﬁciency of generic prescription drug policies to
support public health initiatives in the developed world. This
article will be followed by several articles that go into greater
depth in speciﬁc areas.Deﬁnition of Generic Drugs
In any evaluation of generic drugs and policies, deﬁnition is a key
issue. There is signiﬁcant disparity around the deﬁnition of both
a branded, innovator, original drug and its bioequivalent,on behalf of International Society for Pharmacoeconomics and
epartment of Health Policy and Health Economics, Eötvös Loránd
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 4 6 – 3 5 1 347interchangeable generic version meeting the bioavailability
threshold. For this article, we use the term generic drug in
concordance with the deﬁnition from the World Health Organ-
ization: A generic drug is a pharmaceutical product usually
intended to be interchangeable with an innovator product that
is manufactured without a license from the innovator company
and marketed after the expiry date of the patent or other
exclusive rights [4]. We will consistently refer to the innovator
drug as the original drug and assume the generic drug to be
considered interchangeable within currently described generic
drug policies.Importance of Generic Drugs
In health care systems of developed countries, pharmaceuticals
play a central role in the practice of medicine and patients are
increasingly treated with off-patent drugs [5,6].
Once the patent of a commercially successful, original pharma-
ceutical has expired and exclusivity rights are lost, several generic
manufacturers proceed with the production and commercialization
of the drug. The market authorization process is simpliﬁed because
of substantial scientiﬁc evidence behind the original drugs from
clinical trials and real-world evidence from many patient-years
demonstrating the effectiveness and safety of the compound.
The most important policy objective of health care systems is
to improve the health status of the population [7]. The success of
pharmaceutical innovation over the last few decades has
improved the health status of patients for most major diseases,
reducing the unmet medical need for new pharmaceutical thera-
pies. In disease areas with the greatest public health burden (e.g.,
cardiovascular diseases, mental health, and diabetes mellitus [8])
ﬁrst-line therapy is usually off-patent medicines [9–11]. There-
fore, the success of public health programs in improving the
health status of the total population—in addition to preventiveTable 1 – Common generic drug policy interventions and
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NA, not applicable.health care services and accessibility to primary health care
services—is highly dependent on the availability and appropriate
utilization of off-patent drugs.
The price differential between original and generic pharma-
ceuticals is usually signiﬁcant, but often extremely variable, and,
to some degree, depends on the strength of price regulation [12].
Because of scarcity of health care resources, original patented
drugs are increasingly used only for those patients who cannot
beneﬁt from existing low-priced generic drugs. The number of
patients on original drug therapies is limited; thus, improvement
in health status based on these small groups may not apply to
the total population. Therefore, the major societal beneﬁt of
original drugs is the improved equity in access to effective
therapies for those patients with relatively greater unmet
medical need.Components of Generic Drug Policies
Market authorization criteria for generic drugs are simpliﬁed
compared with those for original pharmaceuticals. After market
entry, generic substitution, international nonproprietary name
prescribing, price control for generics, generic reference pricing,
and tenders are widely used measures to promote the uptake of
generic drugs at the lowest drug acquisition cost [13,14]. Policy-
makers have several options to incentivize stakeholders to abide
by generic drug policies [15–17]. These tools appear to inﬂuence
each other; thus, generic drug policies commonly include mixed
approaches applied by decision makers and health policy
experts with the ultimate aim to accelerate price erosion and
penetration of generics. In Table 1, a nonexclusive list of differ-
ent policy options for generic prescription drugs is presented,
with their expected societal beneﬁts related to different
stakeholders.their expected societal beneﬁts
beneﬁt related to different stakeholders
(physicians
alth care
iders)
Pharmacies Patients
erapeutic
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Opportunity for drug
substitution
Increased accessibility
to lower-priced drugs
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substitution by
considering the
socioeconomic
status of patients
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burden on patients
NA Reduced ﬁnancial
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cribing
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 4 6 – 3 5 1348Success Criteria of Generic Drug Policies
Policy tools given in Table 1 are used to increase savings from the
use of generic drugs to support cost-containment objectives. Price
erosion and market share of generics are often considered a
proxy for the success of drug policies by health care policymakers
[6,18].
There is not much evidence, however, that either one of
these benchmarks is an indicator of achievement of good health
status, a main policy objective in health care systems world-
wide. Generic drug policy interventions are intended to assure
that health outcomes are maintained, or even improved, in
parallel with the reduction in health care expenditure [3].
Therefore, the efﬁciency of generic drug policies can be deﬁned
as reduction in health care expenditure without compromising
health outcomes. This deﬁnition is based on the disinvestment
aspect of generic drug policies. The efﬁciency of generic drug
policies can also be deﬁned from an investment perspective,
especially in those countries with volume limits for the use
of original patented drugs: increase in population health gain
by improved patient access with no increase in health
expenditure.
Several factors may attenuate the efﬁciency of generic drug
policies related to both health outcomes and health expenditure
objectives. Proof of bioequivalence to the originator or reference
product is a mandatory requirement for the registration of
generic drugs in most countries; however, evidence on therapeu-
tic equivalence may be limited [19]. In addition, although two
different generic drugs may be bioequivalent to the reference
drug, they may not be bioequivalent to each other because the
range of bioequivalence intervals may not overlap if one remains
in the upper range of the conﬁdence interval to the reference
product and the other in the lower range. The efﬁcacy or safety
proﬁle of nonbioequivalent generic products can be different,
which may limit their interchangeability. This is especially true
for drugs with a narrow therapeutic window (e.g., warfarin and
cyclosporin) [20–22]. Differences in drug administration, such as
inhaler devices, can also inﬂuence therapeutic equivalence and
may result in negative health outcomes in the case of generic
substitution [23,24].
Drug shortages have become an increasing concern in global
health care. Consequences are limited access to effective thera-
pies and increased cost for purchase of suitable compensatory
medication or therapy. Drug shortages occur more frequently
with less expensive drugs, and reasons are often connected to the
lowest price–driven drug policies [25–27]. Lowest cost drugs areFig. 1 – Success criteria forpurchased from several countries or manufactured locally and
may not keep up with manufacturing to meet demand, resulting
in shortages, or lower-quality output.
Frequent generic drug substitution may result in increased
adverse effects and decreased tolerability [28] and patient con-
fusion [29]. Generic drug substitution in hospitals may result in
medication errors by care personnel [30].
The real-world health gain for patients with chronic diseases
depends on their persistence and adherence with maintenance
drug therapies. Lower co-payments may improve the accessibility
of medication for patients, and therefore improve their adher-
ence to drug therapies [31,32]. However, changes in drug for-
mulations, color of tablets, and pack size as a consequence of
generic drug prescribing or regular revision of generic reference
products may decrease medical adherence [33] and persistence
[34], especially in vulnerable patient populations such as elderly
patients with several comorbidities [35,36], less educated
patients, immigrants [37], or patients with psychiatric illnesses
[38]. Regular switching of drug therapies for chronic diseases may
lead to poorer adherence [39], which may result in an increase in
hospitalizations [40–42]. The impact of generic drug demand and
supply policies on generic drug price erosion can be limited in
certain countries [43]. As a consequence of all the above-
mentioned factors, current generic drug policies may not always
decrease the overall health care expenditure or guarantee equal
health outcomes [44–46]. A recent systematic literature review
conﬁrmed that a signiﬁcant proportion of published articles
opposed the use of generic drugs [3]. By considering these factors,
we propose that multiple success criteria should be applied to
assess the efﬁciency of generic drug policies, as depicted in
Figure 1. Further research is needed to validate whether the list
of criteria is exhaustive or should be extended, or even should be
simpliﬁed to ensure its applicability in routine practice.Importance of Consistent Drug Therapy for Patients
with Chronic Diseases
Implications of inconsistent drug therapy for patients with chronic
diseases may be underestimated when assessing the success of
generic drug policies [47]. Physicians often have a strong prefer-
ence to continue prescribing the branded drug for patients with
chronic diseases after patent expiry [48]. This is especially true in
special disease areas, such as schizophrenia. If patients with
schizophrenia are switched back and forth among different drug
formulations, their conﬁdence in drug therapy may deteriorate,
and therapy discontinuation may increase [49]. Although non-generic drug policies.
Table 2 – Potential outcomes of hypothetical generic drug policy scenarios in schizophrenia.
Scenario Patients continue drug
therapy on preferred off-
patent therapy
Patients are frequently switched
between off-patent drugs
Patients are switched to a
patented drug
Persistence Maintained Relatively poor Maintained
Health
out-
comes
Same as before patent expiry Increased rate of clinical events Similar to health outcomes before
patent expiry
Health
care
costs
Savings in drug budget Savings in drug budget Increased pharmaceutical costs
Increased costs in primary and specialty
care
Overall
societal
impact
Societal gain (savings with equal
health outcomes)
Uncertain (savings in drug budget,
increased nondrug costs, inferior health
outcomes)
Societal loss (increased drug costs
with no improvement in health
outcomes)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 4 6 – 3 5 1 349persistence of patients reduces direct pharmaceutical costs, the
health status of patients without drug therapy can decline. Acute
schizophrenic events may increase the cost of inpatient care, and
therefore the cost-savings potential on the total health expendi-
ture after patent expiry can be difﬁcult to predict.
To minimize such switching induced by generic substitution
policies, physicians may prescribe patented drug therapies to
prevent stable patients with schizophrenia from switching
back and forth among different generic drug formulations [50].
In such cases, patients can stay on effective drugs without the
risk of substitution by pharmacists. This scenario results in
potentially equal health gain with increased pharmaceutical
expenditure.
The example of schizophrenia shows how persistence with
drug therapy after patent expiry inﬂuences the success of generic
drug policies in some chronic diseases (Table 2).Economic Value of Different Generic Drug Policies
The value of innovative pharmaceuticals depends on multiple
criteria that differentiate the innovator product from otherFig. 2 – Example for multicriteria value assessment of chronic maavailable treatments [51]. A similar approach can be used to
illustrate the value of generic drug policies, where the individual
components that comprise value include cost, quality, and out-
comes as demonstrated by a waterfall diagram (Fig. 2).
Patent protection provides additional value for new original
drug manufacturers compared with off-patent medicine manu-
facturers. Two policy scenarios can be differentiated for off-
patent drugs. In the ﬁrst scenario with multiple criteria policy
objectives, there would be more regulatory control on the bio-
equivalence criterion, and regulators often check product quality.
Payers would not force patients to switch to the least expensive
generic drug. Therefore, patients can stay on the same off-patent
drug formulations for longer periods, and their adherence and
persistence may remain more stable. This may lead to health
outcomes equal to those with original pharmaceuticals, without
an increase in nonpharmaceutical cost of care. This policy
scenario adds differential value to an alternative policy scenario
in which the maximization of generic drug price erosion serves
the only policy objective. The added value of the multiple criteria
policy scenario compared with the lowest price policy scenario is
that such methods can be country speciﬁc. Further local research
is needed to quantify the potential magnitude of multicriteriaintenance off-patent drugs. R&D, research and development.
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major markets.Conclusions
Pharmaceutical policymakers tend to focus on improving
patented drug policies because they are under pressure from
patients, physicians, and manufacturers to increase access
to novel therapies. Most of the patients, however, are treated
with off-patent medicines; therefore, the success of public
health programs in improving the health status of the total
population is highly dependent on the efﬁciency of generic drug
policies.
Researchers and policymakers often assess the efﬁciency of
generic drug policies by measuring the level of price erosion and
market share of generics. Drug quality, bioequivalence, in some
cases drug formulations, supply reliability, medical adherence
and persistence, health outcomes, and nondrug costs, however,
are also attributes of success for generic drug policies.
In conclusion, further methodological research is needed to
understand and improve the efﬁciency of generic drug policies.
This also requires expansion of the evidence base concerning the
use of generic drugs and the impact of generic drug policies,
based, in part, on real-world evidence. The development of
applications of multicriteria decision analysis may assist policy-
makers and researchers to assess the true value of off-patent
drugs and drug policies.
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